Nuvectis Pharma, Inc. Stock Price, News & Analysis

Nuvectis Pharma (NASDAQ: NVCT) has announced the initiation of its Phase 1b program for NXP900, following successful completion of dose escalation and drug-drug interaction studies. The program consists of two components: a single-agent study evaluating NXP900 in patients with specific genetic alterations, and a combination study with EGFR and ALK inhibitors in NSCLC patients who developed treatment resistance.

The single-agent component targets patients with YES1 amplification, FAT1 mutations in NSCLC, NF2 mutations in mesothelioma and renal cancer, and other solid tumors with relevant Hippo Pathway alterations. The combination study, expected to start later in 2025, will focus on NSCLC patients who developed resistance to existing treatments.

Nuvectis Pharma (NASDAQ: NVCT) reported significant progress in Q2 2025, highlighted by the successful completion of NXP900's Phase 1a dose escalation study in advanced solid tumors and a drug-drug interaction study in healthy volunteers. The company strengthened its financial position with a proforma cash balance of $39 million as of June 30, 2025, following an ATM share acquisition by a healthcare-focused institutional investor in July.

The company reported a net loss of $6.3 million for Q2 2025, compared to $4.4 million in Q2 2024. R&D expenses increased to $3.6 million, while G&A expenses rose to $3.0 million. The current cash position is expected to fund operations into second half of 2027, with plans to initiate the NXP900 Phase 1b program imminently and explore NXP800's potential in endometrial and prostate cancers.

Nuvectis Pharma (NASDAQ: NVCT) has announced final clinical data from two key studies. The NXP800 Phase 1b study in ovarian cancer showed mixed results with 2 partial responses and 3 stable diseases among 13 evaluable patients with recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. While demonstrating biological activity, the company will discontinue development in ovarian cancer but explore opportunities in other cancers.

The company also reported successful completion of the NXP900 Phase 1a dose escalation study and drug-drug interaction study. The Phase 1a study evaluated doses from 20 to 300 mg/day, showing mainly mild to moderate gastrointestinal side effects and approximately 90% inhibition of SRC kinase phosphorylation at doses ≥150 mg/day. The Phase 1b program for NXP900, both as monotherapy and in combination with other anti-cancer agents, is expected to begin in the coming weeks.

Nuvectis Pharma (NASDAQ: NVCT) has successfully completed a drug-drug interaction (DDI) study for NXP900 in healthy volunteers. The study revealed that NXP900 is classified as a weak inhibitor of CYP3A, supporting its potential combination with EGFR and ALK inhibitors in non-small cell lung cancer (NSCLC) treatment.

The study involved 14 healthy volunteers and showed NXP900 increased Midazolam concentration by less than 2-fold. No serious adverse events were reported, with only mild to moderate diarrhea and non-infection related white blood cell count increases observed.

The company is completing its Phase 1a dose escalation study and plans to advance to Phase 1b testing, which will evaluate NXP900 both as a single agent and in combinations with leading EGFR and ALK drugs in patients whose cancers may be sensitive to SRC/YES1 inhibition.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.

Nuvectis Pharma reported its Q1 2025 financial results and business updates. The company presented promising NXP900 Phase 1a clinical data at AACR 2025, showing robust pharmacodynamic response and acceptable safety in advanced cancer patients. Nuvectis completed a $15.5M financing, extending cash runway into Q1 2027. Financial highlights include: cash position of $29.9M as of March 31, 2025 (up from $18.5M in December 2024), and a net loss of $5.3M (vs $4.2M in Q1 2024). R&D expenses were $3.7M, while G&A expenses reached $1.9M. The company is preparing for NXP900's Phase 1b study and continues enrollment in the NXP800 Phase 1b trial for platinum-resistant, ARID1a mutated ovarian cancer, with updates expected in the coming months.

Nuvectis Pharma presented key findings for their cancer drug NXP900 at the 2025 AACR Meeting. The Phase 1a dose-escalation study, involving 29 patients with advanced cancers, demonstrated promising results with doses up to 250 mg/day showing an acceptable safety profile.

Key highlights:

• Treatment achieved robust pharmacodynamic responses at tolerated doses
• SRC inhibition exceeded 90% after a single dose
• Most side effects were Grade 1-2, including fatigue and nausea
• Median patient age was 62 years, with 62% males

Three preclinical posters revealed NXP900's potential in NSCLC (non-small cell lung cancer), both as a single agent and in combination with existing therapies. The company plans to commence Phase 1b trials targeting patients with YES1 gene amplifications and hippo pathway alterations, as well as exploring combinations with market-leading therapies for resistant NSCLC.

Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced upcoming presentations for their product NXP900 at the 2025 American Association for Cancer Research Meeting (AACR). The conference will be held from April 25th to April 30th in Chicago, IL. The company focuses on developing innovative treatments for serious unmet medical needs in cancer treatment.

Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place from March 17th-19th in Dana Point, California, where Ron Bentsur, Chairman and Chief Executive Officer, will engage in a fireside chat discussion.

The conference participation highlights Nuvectis's continued engagement with the investment community and its focus on developing innovative treatments for serious unmet medical needs in cancer therapy.